Multiple sclerosis progression

Autor: Tanja Kuhlmann, Marcello Moccia, Timothy Coetzee, Jeffrey A Cohen, Jorge Correale, Jennifer Graves, Ruth Ann Marrie, Xavier Montalban, V Wee Yong, Alan J Thompson, Daniel S Reich, Maria Pia Amato, Brenda Banwell, Frederik Barkhof, Jeremy Chataway, Tanuja Chitnis, Giancarlo Comi, Tobias Derfuss, Marcia Finlayson, Myla Goldman, Ari Green, Kerstin Hellwig, Daphne Kos, Aaron Miller, Ellen Mowry, Jiwon Oh, Amber Salter, Maria Pia Sormani, Mar Tintore, Helen Tremlett, Maria Trojano, Anneke van der Walt, Sandra Vukusic, Emmaunelle Waubant

Publikováno v: International Advisory Committee on Clinical Trials in Multiple Sclerosis 2023, ' Multiple sclerosis progression : time for a new mechanism-driven framework ', The Lancet Neurology, vol. 22, no. 1, pp. 78-88 . https://doi.org/10.1016/S1474-4422(22)00289-7

Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—relapsing-remitting, secondary progressive, and primary progressive—for patient care, research, and regulatory approval of medications. Accumulating evidence

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c95d190a07ae620fd13c1f9545253e9
https://doi.org/10.1016/s1474-4422(22)00289-7